Examkin

Question

Difficulty: HardMonitoring and Treatment Evaluation

A 19-year-old woman presents to the emergency department exactly 44 hours after a suspected intentional ingestion of an unknown quantity of extra-strength acetaminophen tablets. She is currently asymptomatic, with stable vital signs and an unremarkable physical examination. The physician plans a comprehensive management and monitoring strategy to prevent irreversible hepatotoxicity. Arrange the following steps in the correct chronological sequence for the guideline-concordant diagnostic evaluation, clinical monitoring, and therapeutic progression for this patient.

  1. 1Obtain a baseline serum acetaminophen concentration and a comprehensive hepatic aminotransferase panel.
  2. 2Utilize the Rumack-Matthew nomogram to establish the indication for antidote therapy.
  3. 3Initiate an intravenous infusion of N-acetylcysteine while closely monitoring for cutaneous flushing or bronchospasm.
  4. 4Repeat the measurement of serum acetaminophen, AST, and ALT prior to the completion of the 21-hour infusion regimen.
  5. 5Discontinue N-acetylcysteine therapy after confirming an undetectable drug level and improving or normal transaminases.

Answer

The correct chronological sequence is to obtain baseline 4-hour laboratories, plot the concentration on the Rumack-Matthew nomogram, initiate N-acetylcysteine with anaphylactoid monitoring, re-evaluate transaminases and drug levels near the end of the 21-hour protocol, and finally discontinue the infusion once clearance and safety are confirmed.
The established protocol for an acute, single-time ingestion of acetaminophen mandates awaiting the 4-hour mark for accurate nomogram plotting. Once obtained, therapy is guided entirely by this nomogram. If indicated, intravenous N-acetylcysteine is initiated alongside close clinical observation for non-allergic anaphylactoid reactions (such as flushing or bronchospasm). Crucially, the 21-hour protocol is not rigidly fixed; rather, patient evaluation and repeat laboratory monitoring (AST, ALT, and serum acetaminophen levels) dictate when the infusion can be safely terminated.

Step-by-Step Solution

1
Draw a 4-hour serum acetaminophen level and hepatic aminotransferases.
Provides an interpretable baseline value.
Acetaminophen levels drawn prior to 4 hours post-ingestion cannot be accurately risk-stratified on the nomogram due to ongoing gastrointestinal absorption.
2
Plot the result on the Rumack-Matthew nomogram.
Determines if the patient is at risk for hepatotoxicity.
The nomogram mathematically defines the threshold above which N-acetylcysteine therapy is strictly indicated.
3
Start IV N-acetylcysteine and monitor for adverse reactions.
Replenishes glutathione stores while ensuring patient safety.
N-acetylcysteine is virtually 100% effective at preventing liver damage if started within 8 hours. The intravenous formulation carries a known risk of rate-related anaphylactoid reactions, necessitating close observation.
4
Re-check acetaminophen levels and LFTs near the end of the 21-hour infusion.
Assesses for ongoing toxicity and drug clearance.
Some patients exhibit delayed absorption or massive ingestions requiring extended antidote therapy beyond the standard 21 hours, making reassessment mandatory.
5
Discontinue N-acetylcysteine if clinical criteria are met.
Safely concludes therapy.
Therapy can only be definitively stopped when the acetaminophen level is undetectable and transaminases are normal or conclusively trending downward.

Key Concept

Monitoring and Treatment Evaluation for Acetaminophen Overdose
Estimated Time:2m 0s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic